

# Provention Bio to Present at the Virtual H.C. Wainwright BioConnect Conference

RED BANK, N.J., Jan. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will present at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.

A replay of the pre-recorded fireside chat will be available beginning Monday, January 10, at 7:00 am E.T. and can be accessed by visiting the Events and Webcasts section of the Company's website:

<http://investors.proventionbio.com/events>. The webcast will be archived on the Company's website for 30 days following the presentation. A copy of the presentation will also be posted on the company's corporate website in the investor's section.

## About Provention Bio, Inc.:

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including type 1 diabetes, celiac disease and lupus. Visit [www.ProventionBio.com](http://www.ProventionBio.com) for more information and follow us on Twitter: @ProventionBio.

## Internet Posting of Information:

Provention Bio, Inc. uses its website, [www.proventionbio.com](http://www.proventionbio.com), as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

## Investor Contacts:

Robert Doody, VP of Investor Relations  
[rdood@proventionbio.com](mailto:rdood@proventionbio.com)  
484-639-7235

Sam Martin, Argot Partners  
[proventionbio@argotpartners.com](mailto:proventionbio@argotpartners.com)  
212-600-1902

## Media Contact:

Lori Rosen, LDR Communications  
[lori@ldrcommunications.com](mailto:lori@ldrcommunications.com)  
917-553-6808

SOURCE Provention Bio, Inc.

---

<https://investors.proventionbio.com/2022-01-06-Provention-Bio-to-Present-at-the-Virtual-H-C-Wainwright-BioConnect-Conference>